Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...
Eli Lilly's new U.S. facility will be just the first of four that it plans to build in the country. The company expects to ...
Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...
On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
Stocktwits on MSN
Cipla Shares Fall To Biggest Intra-day Lows In Six Months Despite Eli Lilly Deal For Diabetes Drug
Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India ・Tirzepatide is used to manage type 2 ...
The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company’s ...
Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...
Cipla has partnered with Eli Lilly and Company (India) to distribute & promote Tirzepatide in India under a second brand name, Yurpeak, aiming to expand access to innovative treatments for chronic ...
US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...
We asked five academics with expertise in sexual health, nutrition, psychiatry, bioethics and drug policy. Here’s what they said.
Shares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback